JamesEThompsonMDM.S.(He/Him)

Hematologic Oncology

Attending Physician

Dr. Thompson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Northwestern UniversityMS, Medical Informatics, 2013 - 2018
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Pennsylvania Health SystemResidency, Internal Medicine, 1997 - 2001
Columbia University Vagelos College of Physicians and SurgeonsClass of 1997

PubMed

6 citations
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Naval G Daver, Pau Montesinos, Daniel J DeAngelo, Eunice S Wang, Nikolaos Papadantonakis
The Lancet. Oncology. 2024-03-01
14 citations
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Neil P Shah, Ravi Bhatia, Jessica K Altman, Maria Amaya, Kebede H Begna
Journal of the National Comprehensive Cancer Network. 2024-02-01
3 citations
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
Aaron N Winn, Ehab Atallah, Jorge Cortes, Michael W N Deininger, Vamsi Kota
JAMA Network Open. 2023-12-01

Abstracts/Posters

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study
James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid...
James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone
James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Quantification of Humoral Immune Response to Influenza Vaccination in MDS
James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia
James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A ...
James E. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all